Although the specific efficacy and safety in different kidney disease subtypes still require further clinical trials, current evidence supports SGLT-2 inhibitors as a multi-target renal protective agent with broad potential applications in the management of CKD (129). The gene discussed is SLC5A2; the disease is kidney disorder.